Disease Topics

Disease Topics

48 Disease areas packed with insight

Disease Topics

Knowledge Centres

Diagnosis, patient management, treatment strategies & decision support

Drug Database

Drug Database

Summary information on thousands of prescription drugs available in 9 languages

News

News

News written for doctors around pharmacological development

Treatment Guidelines

Clinical Guidelines

Professional association and governmental guidance on treatment

Disease Topics

Clinical Trials

Medical research & drug development - current and past landmark studies

Medical Journals

Medical Journals

Journal articles, titles and extracts from respected publishers

Disease Topics

Medical Apps

All the latest free and paid-for Apps selected for doctors

Welcome to epgonline.org - the website for healthcare professionals

What's new? The Type 2 Diabetes Knowledge Centre

Based on current estimates, the global prevalence of type 2 diabetes has increased almost 10 fold since 1985 and is expected to rise to 552 million by 2030,1 and when absolute numbers of people with diabetes are considered, it is South East Asia and the West Pacific that are expected to experience the highest increases in prevalence over the coming years.2

Type 2 diabetes can be defined according to fasting plasma glucose (FPG) and 2 hour plasma glucose levels. The first is assessed after 8-10 hours of fasting, usually in the morning. The second is measured by an oral glucose tolerance test (OGTT) assessing venous plasma glucose 2 hour after ingestion of a 75g oral glucose load.

Type 2 Diabetes involves two primary pathogenic mechanisms; insulin resistance and impaired insulin secretion. Insulin resistance occurs when the insulin in the body does not exert sufficient action proportional to its blood concentration.3,4 Impaired insulin secretion is characterised by decreased glucose responsiveness, and is observed before the clinical onset of disease.4

Latest News

European Commission approves Eliquis for Deep Vein Thrombosis and Pulmonary Embolism- BMS + Pfizer

30-Jul-2014

Bristol-Myers Squibb Company and ...

European Commission approves Gazyvaro for treatment of CLL- Roche

30-Jul-2014

Roche today announced that the ...

CHMP recommends updates for Vipidia, Vipdomet and Incresync for T2D-Takeda

30-Jul-2014

The EMA's Committee for Medicinal ...

FDA expands approval of Imbruvica for CLL-Janssen Biotech/Pharmacyclics

30-Jul-2014

The FDA has approved the supplemental ...

FDA approves Solo Smart valve for Aortic Valve Disease-Sorin

30-Jul-2014

Sorin Group has received FDA approval ...

TC 5214 discontinued for Overactive Bladder-Targacept

30-Jul-2014

Targacept has announced top-line ...

EU approves Simbrinza for Glaucoma and Ocular Hypertension-Alcon/Novartis

29-Jul-2014

Alcon has announced that Simbrinza ...

Recent Updates

Drugs

Clinical Guidelines

The Hospital Management of Hypoglycaemia in Adults with Diabetes Mellitus

Guidelines on Chronic Pelvic Pain

Hypertension in pregnancy. The management of hypertensive disorders during pregnancy

Diagnosis and management of chronic kidney disease

Medical Journals

Spring and summer eruption of the elbows: A peculiar localized variant of polymorphous light eruption

Symptoms of airway reflux predict exacerbations and quality of life in bronchiectasis

Contemporary Urethral Stricture Characteristics in the Developed World

Intermediate phenotypes in patients with autosomal dominant hyper-IgE syndrome caused by somatic mosaicism

epgonline.org Social